共 50 条
- [21] Report of Canonical BCR-ABL1 Fusion in GlioblastomaJCO PRECISION ONCOLOGY, 2021, 5 : 1348 - 1353Pang, YingYu, GuangyangButler, MadisonSindiri, SivasishSong, Young K.Wei, Jun S.Wen, XinyuChou, Hisen-ChaoQuezado, MarthaPack, SvetlanaXi, LiqiangAbdullaev, ZiedKim, OlgaRanjan, AliceMerchant, MythiliAntony, RamyaBoris, LisaAboud, OrwaKamson, DavidKaplan, RosandraMackey, MeganCamphausen, KevinZaghloul, KareemArmstrong, Terri S.Gilbert, Mark R.Aldape, KennethHoldhoff, MatthiasKhan, JavedWu, Jing
- [22] Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineBLOOD, 2014, 124 (04) : 511 - 518Branford, SusanYeung, David T.Parker, Wendy T.Roberts, Nicola D.Purins, LeanneBraley, Jodi A.Altamura, Haley K.Yeoman, Alexandra L.Georgievski, JasminaJamison, Bronte A.Phillis, StuartDonaldson, ZoeLeong, MaryFletcher, LindaSeymour, John F.Grigg, Andrew P.Ross, David M.Hughes, Timothy P.
- [23] Screening for BCR-ABL1 in Patients with an Isolated EosinophiliaCLINICAL LABORATORY, 2016, 62 (10) : 2073 - 2074Langabeer, Stephen E.
- [24] A review of the challenge in measuring and standardizing BCR-ABL1CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2017, 55 (10) : 1465 - 1473Yu, ShupingCui, MingHe, XiaoJing, RongrongWang, Huimin
- [25] Chronic Myeloid Leukemia: Beyond BCR-ABL1Current Hematologic Malignancy Reports, 2018, 13 : 435 - 445Ting ZhouL. Jeffrey MedeirosShimin Hu
- [26] Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 MutantsCANCER CELL, 2019, 36 (04) : 431 - +Eide, Christopher A.Zabriskie, Matthew S.Stevens, Samantha L. SavageAntelope, OrlandoVellore, Nadeem A.Than, HeinSchultz, Anna ReisterClair, PhillipBowler, Amber D.Pomicter, Anthony D.Yan, DongqingSenina, Anna, VQiang, WangKelley, Todd W.Szankasi, PhilippeHeinrich, Michael C.Tyner, Jeffrey W.Rea, DelphineCayuela, Jean-MichelKim, Dong-WookTognon, Cristina E.O'Hare, ThomasDruker, Brian J.Deininger, Michael W.
- [27] shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistanceBLOOD, 2015, 125 (11) : 1772 - 1781Khorashad, Jamshid S.Eiring, Anna M.Mason, Clinton C.Gantz, Kevin C.Bowler, Amber D.Redwine, Hannah M.Yu, FanKraft, Ira L.Pomicter, Anthony D.Reynolds, Kimberly R.Iovino, Anthony J.Zabriskie, Matthew S.Heaton, William L.Tantravahi, Srinivas K.Kauffman, MichaelShacham, SharonChenchik, AlexBonneau, KyleUllman, Katharine S.O'Hare, ThomasDeininger, Michael W.
- [28] Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemiaLEUKEMIA RESEARCH, 2014, 38 (01) : 10 - 20Soverini, SimonaBranford, SusanNicolini, Franck E.Talpaz, MosheDeininger, Michael W. N.Martinelli, GiovanniMueller, Martin C.Radich, Jerald P.Shah, Neil P.
- [29] The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (06) : 501 - 506Shanmuganathan, NaranieBranford, Susan
- [30] A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like LeukemiasFRONTIERS IN PHARMACOLOGY, 2021, 12Montecchini, OksanaBraidotti, StefaniaFranca, RaffaellaZudeh, GiuliaBoni, ChristianSorio, ClaudioToffoletti, EleonoraRabusin, MarcoTommasini, AlbertoDecorti, GiulianaStocco, Gabriele